Multiple sclerosis in Peru. A clinical-epidemiological description of a series of patients;Esclerosis múltiple en Perú. Descripción clinicoepidemiológica de una serie de pacientes

Revista de Neurologia

Volumn 41, Issue 10, 2005, Pages 591-595

  Vizcarra Escobar, Darwin ^a,b   Cava Prado, L ^a   Tipismana Barbaran M ^a  

^a HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^b Clínica San Felipe   (Peru)

Author keywords

Cerebrospinal fluid; Clinical features; Epidemiology; Multiple sclerosis; Optic neuritis; Peru

Indexed keywords

ADULT; AGE DISTRIBUTION; ATAXIA; CEREBELLUM DISEASE; CEREBROSPINAL FLUID; CONVULSION; DATA ANALYSIS; DYSPHAGIA; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PERU; RATING SCALE; REVIEW; RISK FACTOR; SEX RATIO; SPHINCTER; SURVIVAL RATE; TREMOR; VERTIGO; ADOLESCENT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PERU; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 33644818347     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4110.2005213     Document Type: Review

References (71)

1. Noseworthy J, Lucchnetti C, Rodríguez M, Weinshenker B. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Comptsom A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
3. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definitive multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-45.
4. Neumann H. Molecular mechanisms of axonal damage in inflammatory central nervous diseases. Curr Opin Neurol 2003; 16: 267-73.
5. Grigoriadis N, Ben-Hur T, Karussis D, Milonas I. Axonal damage in multiple sclerosis: a complex issue in a complex disease. Clin Neurol Neurosurg 2004; 106: 211-7.
6. Ruffini F, Kennedy T, Antel J. Inflammation and remyelination in the central nervous system: a tale of two systems. Am J Pathol 2004; 164: 1519-22.
7. Althaus H. Remyelination in multiple sclerosis: a new role for neurotrophins? Prog Brain Res 2003; 146: 415-32.
8. Kurtzke J. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 1975; 51: 110-36.
9. Kurtzke J. MS epidemiology worldwide. One review of current status. Acta Neurol Scand 1997; 161 (Supp l): 23-33.
10. Hogancamp W, Rodríguez M, Weinshenker B. The epidemiology of multiple sclerosis. Mayo Clin Proc 1997; 72: 871-8.
11. Frohman E. Multiple sclerosis. Med Clin North Am 2003; 87: 867-97.
12. Comptson A. The genetic epidemiology of multiple sclerosis. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1623-34.
13. The Transatlantic Multiple Sclerosis Genetics Cooperative. A metanalysis of genoma screens in multiple sclerosis. Mult Scler 2001; 7: 3-11.
14. Kurtzke J, Heltberg A. Multiple sclerosis in the Faeroe Islands: an epitome. J Clin Epidemiol 2001; 54: 1-22.
15. Dolei A, Serra C. Multiple sclerosis-associated retrovirus in Sardinian MS Patients. Neurology 2002; 58: 471-3.
16. Koprowski H, DeFreitas E, Harper M, Sandberg-Wollheim M, Sheremata W, Robert-Guroff M, et al. Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature 1985; 318: 154-60.
17. Sanders V, Felisan S, Waddell A, Tourtellote W. Detection of herpes viridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996; 2: 249-58.
18. Sriram S, Stratton C, Yao S, Tharp A, Ding L, Bannan J, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6-14.
19. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001; 344: 319-26.
20. Ascherio A, Zhang S, Hernan M, Olek M, Coplan P, Brodovicz K, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344: 327-32.
21. Filippi M. MRI findings predicting subsequent disease course in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis. Neurol Sci 2001; (Suppl 2): S49-51.
22. Zaffaroni M, Baldini S, Ghezzi A. Cranial nerve, brainstem and cerebellar syndromes in the differential diagnosis of multiple sclerosis. Neurol Sci 2001; (Suppl 2): S74-8.
23. Schumacker F, Beebe G, Kibler R, Kurland L, Kurtzke J, McDowell F, et al. Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552-68.
24. Poser C, Paty D, Scheinberg L, McDonald W, Davis F, Ebers G, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
25. McDonald W, Compston F, Edan G, Goodkin D, Hartung H, Lublin F, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel of the diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-7.
26. Fox C, Bensa S, Bray I, Zajicek J. The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria. J Neurol Neurosurg Psychiatry 2004; 75: 56-60.
27. Fangerau T, Schimrigk S, Haupts M, Kaeder M, Ahle G, Brune N, et al. Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. Acta Neurol Scand 2004: 109: 385-9.
28. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
29. Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, et al. MRI in diagnosis of MS. A prospective study with comparision of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988; 38: 180-5.
30. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38: 1822-5.
31. Barkhof F, Filippi M, Miller D, Scheltens P, Campi A, Polman C, et al. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-69.
32. Tintoré M, Rovira A, Martínez M, Río J, Díaz-Villoslada P, Brieva L, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definitive multiple sclerosis. AJNR Am J Neuroradiol 2000; 21: 702-6.
33. Callegaro D, Goldbaum M, Morais L, Tilbery C, Moreira M, Gavia A, et al. The prevalence of multiple sclerosis in the city of Sao Paulo, Brazil 1997. Acta Nerurol Scand 2001; 104: 208-13.
34. Cabrera-Gómez J, Santana-Capote E, Echazábal N, Díaz A, Casanova M, Gómez L, et al. Estado actual de la esclerosis múltiple en Cuba. Rev Neurol 2000; 31: 482-93.
35. Velásquez-Quintana M, Macías M, Rivera V, Lozano J. Esclerosis múltiple en México: un estudio multicéntrico. Rev Neurol 2003; 11: 1019-22.
36. Carra A, Onaha P, Sinay V, Álvarez F, Luetic G, Bettinelli R, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 2003; 10: 671-6.
37. Sánchez J, Aguirre C, Arcos O, Jiménez I, Jiménez M, León F, et al. Prevalencia de la esclerosis múltiple en Colombia. Rev Neurol 2000; 31: 1101-3.
38. Trelles L, Castro C, Díaz A, Velasco R, Montano S, Meza M, et al. La esclerosis en placas en el Perú. ¿Es más común de lo que se pensaba? Rev Neuro-Psiq 1999; 62: 14-9.
39. Castro C, Velasco V, Huaroto L, Trelles L. ¿Es rara la esclerosis múltiple en el Perú? Rev Per Neurol 1996; 2: 73-9.
40. Liviac JA. Esclerosis múltiple. Correlato clínico- radiológico. Trabajo de investigación para optar el título de especialista en Neurología. Lima: Universidad Nacional Mayor de San Marcos; 2001.
41. Ministerio de Salud del Perú. Historia del Hospital Nacional Cayetano Heredia. URL: http://www.minsa.gob.pe/cheredia/default_archivos/organi/ historia.htm. Fecha última consulta: 10.08.05.
42. Ministerio de Salud. Hospital Nacional Cayetano Heredia. Oficina de Estadística e Informática 2005. Lima: Hospital Nacional Cayetano Heredia; 2005.
43. Arruda W, Scola R, Teive H, Werneck L. Multiple sclerosis: report of 200 cases from Curitiba-Brazil and comparison with other Brazilian series. Arq Neuropsiquiatr 2001; 59: 165-70.
44. Oliveira E, Annes M, Oliveira A. Esclerose múltiple. Estudo clínico de 50 pacientes acompañados no ambulatório de neurología UNIFESPEPM. Arq Neuropsiq 1999; 57: 51-5.
45. Phadke J. Survival pattern and course of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry 1987; 50: 523-31.
46. Pekmezovic T, Jarebinski M, Drulovic J. Childhood infections as risk factors for multiple sclerosis: Belgrade case-control study. Neuroepidemiology 2004; 23: 285-8.
47. Sullivan C, Visscher B, Detels R. Multiple sclerosis and age at exposure to childhood diseases and animals. Neurology 1984; 34: 1144-8.
48. OIT oficina regional para América y el Caribe. URL: http://www.oit.org.pe/gpe/pagina.php?objetivo=26#3. Fecha última consulta: 10.08.05.
49. Gronning M, Albrektsen G, Kvale G, Moen B, Aarli JA, Nyland H. Organic solvents and multiple sclerosis: a case-control study. Acta Neurol Scand 1993; 88: 247-50.
50. Landtblom A, Wastenson M, Ahmadi A, Soderkvist P. Multiple sclerosis and exposure to organic solvents, investigated by genetic polymorphisms of the GSTM1 and CYP2D6 enzyme systems. Neurol Sci 2003; 24: 248-51.
51. Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans: VII. Risk factors for MS. Neurology 1997; 48: 204-13.
52. Gonzales O, Sotelo J. Is the frecuency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 1995; 59: 528-30.
53. Optic Neuritis Study Group. High and low risk profiles for the development of multiple scleroris within 10 years after optic neuritis. Arch Ophthalmol 2003; 121: 944-9.
54. Wang J, Tow S, Aung T, Lim S, Cullen J. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Experiment Ophthalmol 2001; 29: 312-5.
55. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2: 117-27.
56. Frohman EM, Goodin D, Calabresi P, Corboy J, Coyle P, Filippi M, et al. The utility of MRI in suspected MS. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2003; 61: 602-11.
57. Minguetti G. Ressonancia magnética na esclerose mútiple. Nalisé de 270 casos. Arq Neuropsiquiatr 2001; 59: 563-9.
58. Sadaba M, González-Porque P, Masjuan J, Álvarez-Cermeno J, Bootello A, Villar L. An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods 2004; 284: 141-5.
59. Joynt R, Griggs R. Baker's clinical neurology. Philadelphia: Lippincott Williams & Wilkins; 2000.
60. Winkelmann J. HTLV-1 and multiple sclerosis: the link is missing. J Lab Clin Med 1993; 122: 230-1.
61. Sánchez-Palacios C, Gotuzzo E, Vandamme AM, Maldonado Y. Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. Int J Infect Dis 2003; 7: 132-7.
62. Menna-Barreto M, Doval A, Rabolini G, Bianchini O. HTLV-I associated myelopathy in Porto Alegre (Southern Brazil). Arq Neuropsiquiatr 1995; 53: 771-6.
63. Hartmann M, Pfadenhauer K. Intrathecal antibody production against Borrelia burgdorferi in a patient with relapsing-remitting multiple sclerosis. Eur J Neurol 2003; 10: 747-8.
64. Sumelahti M, Tienari P, Wikstrom J, Salminen T, Hakama M. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002; 8: 350-5.
65. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127: 844-50.
66. Pekmezovic T, Jarebinski M, Drulovic J, Stojsavljevic N, Levic Z. Survival of multiple sclerosis patients in the Belgrade population. Neuroepidemiology 2002; 21: 235-40.
67. Achiron A. Predicting the course of relapsing-remitting MS using longitudinal disability curves. J Neurol 2004; 251 (Suppl 5): 65-8.
68. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-8.
69. Ebers G, Koopman W, Hader W, Sadovnik A, Kremenchutzky M, Mandalfino P, et al. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Brain 2000; 123: 641-9.
70. Wallin M, Page W, Kurtzke J. Epidemiology of multiple sclerosis in US veterans VIII. Long-time survival after onset of multiple sclerosis. Brain 2000; 123: 1677-87.
71. Kremenchutzky M. Historia natural de la esclerosis múltiple. Rev Neurol 2000; 30: 967-72.